Loading
IO102-IO103 is an experimental peptide (immunotherapeutic vaccine) from IO Biotech in phase 3 trials for melanoma and head and neck squamous cell carcinoma, aimed at PD-L1.
IO102-IO103 (IO102, IO103) is a peptide (immunotherapeutic vaccine) developed by IO Biotech. Its target is PD-L1 (the sponsor names IDO1 and PD-L1). The sponsor states: IO102-IO103 comprises an IDO peptide antigen (IO102) and a PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) and given subcutaneously to stimulate an immune response against IDO- and PD-L1-expressing cells, dosed alongside pembrolizumab in advanced melanoma. ClinicalTrials.gov describes the intervention as: IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05155254 (IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)), in melanoma and head and neck squamous cell carcinoma. The largest, NCT05155254, plans to enrol 407 participants (actual) with primary completion was scheduled for 2025-05-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
IO102-IO103 comprises an IDO peptide antigen (IO102) and a PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) and given subcutaneously to stimulate an immune response against IDO- and PD-L1-expressing cells, dosed alongside pembrolizumab in advanced melanoma. Connects to PD-L1 and IDO1.
1.IO102-IO103 slips into a pocket on PD-L1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IO102-IO103" OR ABSTRACT:"IO102-IO103" OR TITLE:"IO102" OR ABSTRACT:"IO102" OR TITLE:"IO103" OR ABSTRACT:"IO103") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IO102-IO103, not a curated reading list.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.